TP53 and adenocarcinoma: More specifically, lineage tracing studies have demonstrated that combined loss of P53, RB, and PTEN in cancer cells treated with targeted therapy is necessary for this transdifferentiation switch, i.e., adenocarcinoma to neuroendocrine (small cell phenotype) in both PC and lung tumors [103,139,140,142].